司库奇尤单抗治疗银屑病：患者选择与展望
Secukinumab in the treatment of psoriasis: patient selection and perspectives.
作者信息
Yang Eric J, Beck Kristen M, Liao Wilson
机构信息
Department of Dermatology, University of California San Francisco, San Francisco, CA, USA,
Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA,
出版信息
Psoriasis (Auckl). 2018 Oct 17;8:75-82. doi: 10.2147/PTT.S146004. eCollection 2018.
Abstract
Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly efficacious and well-tolerated. However, several biologic medications are currently approved for the treatment of moderate-to-severe plaque psoriasis, and many demonstrate excellent efficacy and safety. Due to this wide selection, it is often unclear how to choose biologics for specific patients. Important considerations in biologic selection include clinical efficacy, safety, cost, convenience, onset of action, and management of comorbid disease. This article aims to outline the key considerations in patient selection for the treatment of plaque psoriasis with secukinumab.
摘要
司库奇尤单抗是一种靶向白细胞介素-17A的人源单克隆抗体，已获批用于三种适应症：中度至重度斑块状银屑病、银屑病关节炎和强直性脊柱炎。在这三种适应症的III期临床试验中，司库奇尤单抗已被证明具有高效性和良好的耐受性。然而，目前有几种生物药物已获批用于治疗中度至重度斑块状银屑病，许多药物都显示出优异的疗效和安全性。由于选择范围广泛，对于特定患者而言，往往不清楚如何选择生物制剂。选择生物制剂时的重要考虑因素包括临床疗效、安全性、成本、便利性、起效时间以及合并症的管理。本文旨在概述使用司库奇尤单抗治疗斑块状银屑病时患者选择的关键考虑因素。
相似文献
1
Secukinumab in the treatment of psoriasis: patient selection and perspectives.
Psoriasis (Auckl). 2018 Oct 17;8:75-82. doi: 10.2147/PTT.S146004. eCollection 2018.
2
Profile of secukinumab in the treatment of psoriasis: current perspectives.
Ther Clin Risk Manag. 2015 Dec 2;11:1767-77. doi: 10.2147/TCRM.S79053. eCollection 2015.
3
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.
Ther Adv Chronic Dis. 2018 Jan;9(1):5-21. doi: 10.1177/2040622317738910. Epub 2017 Nov 16.
4
Treatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumab.
Clin Cosmet Investig Dermatol. 2016 Oct 11;9:347-355. doi: 10.2147/CCID.S81160. eCollection 2016.
5
Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis.
Indian J Dermatol. 2017 Mar-Apr;62(2):195-199. doi: 10.4103/ijd.IJD_233_16.
6
Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative.
Clinicoecon Outcomes Res. 2018 Aug 30;10:477-491. doi: 10.2147/CEOR.S171560. eCollection 2018.
7
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Acta Derm Venereol. 2022 Apr 27;102:adv00698. doi: 10.2340/actadv.v102.563.
8
Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis: .
Expert Rev Clin Immunol. 2024 May;20(5):435-440. doi: 10.1080/1744666X.2024.2303340. Epub 2024 Jan 10.
9
Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease.
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1161-1173. doi: 10.1111/jdv.16124. Epub 2020 Jan 7.
10
Secukinumab: A Review in Psoriatic Arthritis.
Drugs. 2016 Jul;76(11):1135-45. doi: 10.1007/s40265-016-0602-3.
引用本文的文献
1
Strategies for Optimal Use of Biological Therapies in Managing Psoriasis: Focus on Secukinumab.
Dermatol Ther (Heidelb). 2025 Sep 4. doi: 10.1007/s13555-025-01515-x.
2
A systematic review of the role of interleukin inhibitors in lichen planus: therapeutic and paradoxical effects.
Inflammopharmacology. 2025 Aug 12. doi: 10.1007/s10787-025-01853-4.
3
Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis.
Dermatol Ther (Heidelb). 2025 Jul 17. doi: 10.1007/s13555-025-01463-6.
4
Psoriasis Treatments: Emerging Roles and Future Prospects of MicroRNAs.
Noncoding RNA. 2025 Feb 13;11(1):16. doi: 10.3390/ncrna11010016.
5
An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis.
Curr Drug Targets. 2024;25(5):353-373. doi: 10.2174/0113894501292755240304063020.
6
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics.
Pediatric Health Med Ther. 2023 Nov 14;14:435-451. doi: 10.2147/PHMT.S389108. eCollection 2023.
7
Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis.
J Clin Med. 2022 Mar 9;11(6):1506. doi: 10.3390/jcm11061506.
8
Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action.
Biomedicines. 2022 Feb 20;10(2):498. doi: 10.3390/biomedicines10020498.
9
Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis - a real life retrospective study.
Postepy Dermatol Alergol. 2021 Dec;38(6):973-978. doi: 10.5114/ada.2020.97066. Epub 2020 Jul 11.
10
Secukinumab, Pituitary Enlargement and Panhypopituitarism: Are They Related?
Eur J Case Rep Intern Med. 2021 Dec 31;8(12):003099. doi: 10.12890/2021_003099. eCollection 2021.
本文引用的文献
1
Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2191-2199. doi: 10.1111/jdv.15047. Epub 2018 Jun 27.
2
Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
J Dermatolog Treat. 2018 Dec;29(8):769-774. doi: 10.1080/09546634.2018.1466022. Epub 2018 May 7.
3
Commentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?: A critical question that we are only just beginning to answer.
J Am Acad Dermatol. 2018 Jul;79(1):69-70. doi: 10.1016/j.jaad.2018.03.046. Epub 2018 Apr 3.
4
Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.
Curr Med Res Opin. 2018 Jul;34(7):1325-1333. doi: 10.1080/03007995.2018.1457516. Epub 2018 Apr 23.
5
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Ann Rheum Dis. 2018 Jun;77(6):890-897. doi: 10.1136/annrheumdis-2017-212687. Epub 2018 Mar 17.
6
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).
Arthritis Res Ther. 2018 Mar 15;20(1):47. doi: 10.1186/s13075-018-1551-x.
7
Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.
J Drugs Dermatol. 2018 Mar 1;17(3):247-250.
8
The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study.
J Am Acad Dermatol. 2018 Jul;79(1):60-68. doi: 10.1016/j.jaad.2018.02.050. Epub 2018 Mar 1.
9
Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
Expert Rev Clin Pharmacol. 2018 Apr;11(4):333-344. doi: 10.1080/17512433.2018.1445967. Epub 2018 Mar 6.
10
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514. doi: 10.1111/jdv.14878. Epub 2018 Mar 22.
Zotero 插件